"MEDEZE Group" Appoints Yuanta Securities as Underwriter, Sets IPO Price at 9 Baht per Share, Offering 268 Million Shares, Subscription from October 2–4, 2024. Positive Response from Investors During Roadshow at SET, Showcasing Strong Business Fundamentals and High Growth Potential. Expected to Begin Trading on the SET on October 15, 2024.

Mr. Payupat Mahapol, Managing Director of Investment Banking at Yuanta Securities (Thailand) Co., Ltd., in his capacity as the financial advisor and underwriter for the initial public offering (IPO) of MEDEZE Group Public Company Limited (MEDEZE), revealed that MEDEZE has signed a contract appointing the underwriter for the public offering of common shares. For the IPO of MEDEZE, which involves 268 million shares, the share price was set at 9 baht per share, with a par value of 0.50 baht per share. The share price was determined through a book-building process with institutional investors both from Thailand and abroad. The price-to-earnings ratio (P/E) is 35.55 times, calculated from net profit per share over the last four quarters, from July 1, 2023, to June 30, 2024, which amounts to 270.40 million baht. This is divided by the total number of common shares after the offering, which equals 1,068,000,000 shares, resulting in a net profit per share of 0.25 baht. Investors can subscribe to the shares from October 2-4, 2024, and trading is expected to commence on the Stock Exchange of Thailand by October 15, 2024.

The price-to-earnings ratio (P/E) mentioned above is calculated based on past financial performance, without taking into account future operating results. The proposed offering price aligns with MEDEZE's business fundamentals and the plan to use the funds raised from the public offering to expand the business in the future. This price is considered appropriate for investors. The underwriters for the offering include KGI Securities (Thailand) Public Company Limited, CGS-CIMB Securities (Thailand) Co., Ltd., Krungthai Xspring Securities Co., Ltd., DAOL Securities (Thailand) Public Company Limited, and Globlex Securities Co., Ltd.

The investor presentation, or roadshow, to offer shares to the public for the first time (IPO) at the Stock Exchange of Thailand (SET) in Bangkok on October 1, 2024, received a very positive response from investors. This strong response is attributed to the solid business fundamentals, MEDEZE's leadership in the industry, and the clear plan for future business expansion. Additionally, the business is currently in an uptrend. Currently, MEDEZE has a registered capital of 400 million baht, which represents 800 million shares, and intends to list common shares on the Stock Exchange of Thailand. The public offering will consist of up to 268 million new shares with a par value of 0.50 baht per share, representing no more than 25.09% of the company's issued and paid-up shares after the offering. These shares will be listed in the "SERVICE" sector under the "HEALTH" subcategory of the SET.

Dr. Veerapol Khemarangsan, Chief Executive Officer of MEDEZE Group Public Company Limited (MEDEZE), revealed that the company is a provider of services related to the analysis, separation, cultivation, and storage of stem cells, as well as testing the potential of immune cells (NK Cells). With over 14 years of continuous experience in the industry, MEDEZE offers comprehensive long-term stem cell storage services using innovative and advanced technology. The company operates through five subsidiaries: (1) Medeze NK Co., Ltd., which provides immune cell (NK Cells) potency testing services; (2) Medeze Cosmeceutical Co., Ltd., which sells beauty products under the DAA brand and dietary supplements; (3) Medeze Research and Development Co., Ltd., which conducts experimental research and development in biotechnology; (4) Medeze Treasury Pte. Ltd., an investment company holding and managing the trademarks of the group; and (5) Medeze Group Pte. Ltd., which focuses on experimental biotechnology research and development.

The company has high potential in providing services with a total of 30 liquid nitrogen tanks, capable of processing up to 2,880 blood extraction cases and 4,560 tissue extraction cases per year. It also has the capacity to test the potency of NK Cells with a maximum of 1,920 cases per year. The company has partnerships with 219 hospitals in the country and distributors both domestically and internationally, including in Vietnam, Singapore, Myanmar, Indonesia, and Cambodia. Additionally, MEDEZE employs a large number of leading scientists and experts in the biotechnology field, which strengthens its network with top medical professionals in leading hospitals. The company also operates a Cleanroom Class 100 laboratory with state-of-the-art equipment and technology in the stem cell banking industry, including a cryopreservation system in liquid nitrogen tanks, an automatic blood stem cell separation machine (Auto Xpress), and an automatic stem cell expansion incubator (Quantum).

The company has gained international trust with its global standard cryopreservation system, certified by the Association for the Advancement of Blood and Biotherapies (AABB) from the United States, an organization that provides stringent operational standards for stem cell banks. This certification follows international quality system standards as per the U.S. Food and Drug Administration (U.S. FDA) regulations, covering activities related to umbilical cord blood, from long-term storage to distribution for patient treatment worldwide. Additionally, the company meets Clean Room Class 100 laboratory standards since 2013, accredited by the National Environmental Balancing Bureau (NEBB) from Germany, ensuring proper control of particle levels, pressure, and temperature within the laboratory.

After the fundraising, MEDEZE plans to invest in expanding its business in the Hair Follicle Cell Bank by developing innovative hair follicle cell solutions to address customer needs related to hair and scalp issues, which are expected to increase among the elderly. The company also intends to invest in installing a Robotic Cell Culture System, an advanced and cutting-edge innovation recognized internationally, to improve the safety of the storage process. This system reduces human errors and mitigates risks from environmental variables, enhancing the company's credibility to match that of leading global operators and attracting more customers both domestically and internationally.

In the years 2021-2023, MEDEZE's total revenue was 446.41 million baht, 595.70 million baht, and 701.81 million baht, respectively, with net profits of 112.06 million baht, 147.19 million baht, and 239.57 million baht, respectively.